Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs

Clinical and Experimental Metastasis

Volumn 20, Issue 3, 2003, Pages 265-273

  Graff, Jeremy R ^a   Zimmer, Stephen G ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cyclin D1; eIF 4E; eIF 4F; Growth factors; Invasion; Metastasis; MMP 9; Translation initiation; Tumor progression; VEGF

Indexed keywords

CYCLIN D1; INITIATION FACTOR 4E; MATRIX METALLOPROTEINASE; MESSENGER RNA; PROTEIN BCL 2; RNA BINDING PROTEIN; VASCULOTROPIN;

5' UNTRANSLATED REGION; ANGIOGENESIS; AUTOCRINE EFFECT; CANCER GROWTH; CANCER INVASION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENE REPRESSION; METASTASIS; ONCOGENE C MYC; REVIEW; RNA TRANSLATION; START CODON; TRANSLATION INITIATION; TRANSLATION REGULATION;

ANIMALS; DISEASE PROGRESSION; EUKARYOTIC INITIATION FACTOR-4E; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; UP-REGULATION;

EID: 0037273324     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022943419011     Document Type: Review

References (110)

1. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-41.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
3. Liteplo RG, Frost P, Kerbel RS. Genetic and epigenetic aspects of tumor progression. Basic Life Sci 1985; 33: 285-305.
4. Nicholson GL. Tumor cell instability, diversification, and progression to the metastatic phenotype: From oncogene to oncofetal expression. Cancer Res 1987; 47: 1473-87.
5. Sager R. Expression genetics in cancer: Shifting the focus from DNA to RNA. Proc Natl Acad Sci USA 1997; 94: 952-5.
6. Zimmer SG, DeBenedetti A, Graff JR. Translational control of malignancy: The mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 2000; 20(3A): 1343-51.
7. Zimmer SG, Graff JR. The emerging role for the mRNA cap-binding protein, eIF-4E, in metastatic progression. In Welch DR (ed): Cancer Metastasis-Related Genes. Dordrecht, The Netherlands: Kluwer Academic Publishers 2002; 247-65.
8. Dever TE. Gene-specific regulation by general translation factors. Cell 2002; 108(4): 545-56.
9. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15(7): 807-26.
10. Herbert TP, Tee AR, Proud CG. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem 2002; 277(13): 11591-6.
11. Gingras AC, Kennedy SG, O'Leary MA et al. 4E-BP1, a repressor of the mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev 1998; 12: 502-13.
12. Gingras AC, Gygi SP, Raught B et al. Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism. Genes Dev 1999; 13: 1422-37.
13. Brunn GJ, Hudson CC, Sekulic A et al. Phosphorylation of the translational repressor PHAS-1 by the mammalian target of rapamycin. Science 1997; 277: 99-101.
14. Hara K, Yonezawa K, Kozlowoski MT et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 1997; 272; 26457-63.
15. Haghighat A, Mader S, Pause A et al. Repression of cap-dependent translation by 4E-binding protein 1: Competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J 1995; 14: 5701-9.
16. Minich WB, Balasta ML, Goss DJ et al. Chromatographic resolution of in vivo phosphorylated and nonphosphorylated eukaryotic translation initiation factor eIF-4E: Increased cap affinity of the phosphorylated form. Proc Natl Acad Sci USA 1994; 91(16): 7668-72.
17. Flynn A, Proud CG. Serine 209, not serine 53, is the major site of phosphorylation in initiation factor eIF-4E in serum-treated Chinese hamster ovary cells. J Biol Chem 1995; 270 (37): 21684-8.
18. Joshi B, Cai AL, Keiper BD et al. Phosphorylation of eukaryotic protein synthesis initiation factor 4E at ser-209. J Biol Chem 1995; 270: 14597-603.
19. Waskiewicz AJ, Flynn A, Proud CG et al. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997; 16: 1909-20.
20. Pyronnet S, Imataka H, Gingras AC et al. Human eukaryotic initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF-4E. EMBO J 1999; 18: 270-9.
21. Lachance PE, Miron M, Raught B et al. Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth. Mol Cell Biol 2002; 22(6): 1656-63.
22. Rhoads RE, Joshi-Barve S, Rinker-Schaeffer C. Mechanism of action and regulation of protein synthesis initiation factor 4E: Effects on mRNA discrimination, cellular growth rate, and oncogenesis. Prog Nucleic Acid Res Mol Biol 1993; 46: 183-219.
23. Rao CD, Pech M, Robbins KC et al. The 5′ untranslated sequence of the c-sis/PDGF 2 transcript is a potent translational inhibitor. Mol Cell Biol 1988; 8: 284-92.
24. Wang C, Stiles CD. Regulation of platelet-derived growth factor A messenger RNA translation in differentiating F9 teratocarcinoma cells. Cell Growth Diff 1993; 4: 871-7.
25. Prats H, Kaghad M, Prats AP et al. High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc Natl Acad Sci USA 1989; 86: 1836-40.
26. Kevil C, Carter P, Hu B et al. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene 1995; 11: 2339-48.
27. Noma T, Glick AB, Geiser AG et al. Molecular cloning and structure of the human transforming growth factor-beta 2 gene promoter. Growth Factors 1991; 4: 247-55.
28. Arrick BA, Lee AL, Grendell RL et al. Inhibition of translation of transforming growth factor-beta 3 mRNA by its 5′ untranslated region. Mol Cell Biol 1991; 11: 4306-13.
29. Nilsson FC, Gammeltoft S, Christiansen J. Translational discrimination of mRNAs coding for human insulin-like growth factor II. J Biol Chem 1990; 265: 13431-4.
30. Kevil C, DeBenedetti A, Payne KD et al. Translational regulation for vascular permeability factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis. Int J Cancer 1996; 65: 785-90.
31. Saito H, Hayday AC, Wiman K et al. Activation of the c-myc gene by translocation: A model for translational control. Proc Natl Acad Sci USA 1983; 80: 7476-80.
32. Darveau A, Pelletier J, Sonenberg N. Differential efficiencies of in vitro translation of mouse c-myc transcripts differing in the 5′ untranslated region. Proc Natl Acad Sci USA 1985; 82: 2315-9.
33. DeBenedetti A, Joshi B, Graff JR et al. CHO cells transformed by the translation factor eIF-4E display increased c-myc expression, but require overexpression of Max for tumorigenicity. Mol Cell Diff 1994; 2: 347-71.
34. Zerial M, Toschi L, Ryseek RP et al. The product of a novel growth factor activated gene, fosB, interacts with Jun proteins enhancing their DNA binding activity. EMBO J 1989; 8: 805-13.
35. Hensold JO, Stratton CA, Barth C. The conserved 5′-untranslated leader of Spi-1 (PU.1) mRNA is highly structured and potently inhibits translation in vitro but not in vivo. Nucleic Acids Res 1997; 25: 2869-76.
36. Raught B, Gingras AC, James A et al. Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein beta isoform and up-regulation of the eukaryotic translation initiation factor 2alpha are correlated with neoplastic transformation of mammary epithelial cells. Cancer Res 1996; 56: 4382-6.
37. Calkhoven CF, Muller C, Leutz A. Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev 2000; 14: 1920-32.
38. Landers JE, Haines DS, Strauss JF 3rd et al. Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994; 9: 2745-50.
39. Landers JE, Cassel SL, George DL. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 1997; 57: 3562-8.
40. Capoulade C, Bressac-de Paillerets B, Lefrere I et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 1998; 16: 1603-10.
41. Brown CY, Mize GJ, Pineda M et al. Role of two upstream open reading frames in the translational control of oncogene mdm2. Oncogene 1999; 18: 5631-7.
42. Rosenwald IB, Karatzas A, Sonenberg N et al. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor eIF4E. Mol Cell Biol 1993; 13: 7358-63.
43. Rosenwald EB, Kaspar R, Rosseau D et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D at transcriptional and posttranscriptional levels. J Biol Chem 1995; 270: 21176-80.
44. Rousseau D, Kaspar R, Rosenwald I et al. Translation initiation of omithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci USA 1996; 93: 1065-70.
45. kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. Mol Cell Biol 1996; 16: 4327-36.
46. Hengst L, Reed SI. Translational control of p27kip1 accumulation during the cell cycle. Science 1996; 271: 1861-4.
47. Wood MW, Van Dongen HM, Van Dongen AM. The 5′ untranslated region of the N-methyl-D-aspartate receptor NR2A subunit controls efficiency of translation. J Biol Chem 1996; 271: 8115-20.
48. Child SJ, Miller MK, Geballe AP. Cell type-dependent and -independent control of HER-2/neu translation. Int J Biochem Cell Biol 1999; 31: 201-13.
49. Schindler R, Clark BD, Dinarello CA. Dissociation between interleukin-1 beta mRNA and protein synthesis in human peripheral blood mononuclear cells. J Biol Chem 1990; 265: 10232-7.
50. Bamford RN, Battiata AP, Burton JD et al. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type IR region/IL-15 fusion message that lacks many upstream AUGs that normally attenuate IL-15 mRNA translation. Proc Natl Acad Sci USA 1996; 93: 2897-902.
51. Shantz LM, Pegg AE. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res 1994; 54: 2313-6.
52. Shantz LM, Hu RH, Pegg AE. Regulation of ornithine decarboxylase in a transformed cell line that overexpresses translation initiation factor eIF-4E. Cancer Res 1996; 56: 3265-9.
53. Graff JR, DeBenedetti A, Olson JW et al. Translation of ODC mRNA and polyamine transport are suppressed in ras-transformed CREF cells by depleting translation initiation factor 4E. BBRC 1997; 240: 15-20.
54. Manzella JM, Rychlik W, Rhoads RE et al. Insulin induction of ornithine decarboxylase. Importance of mRNA secondary structure and phosphorylation of eukaryotic initiation factors eIF-4B and cIF4E. J Biol Chem 1991; 266: 2383-9.
55. Grens A, Scheffler IE. The 5′- and 3′-untranslated regions of ornithine decarboxylase mRNA affect the translational efficiency. J Biol Chem 1990; 265: 11810-6.
56. Fagan RJ, Lazaris-Karatzas A, Sonenberg N et al. Translational control of ornithine aminotransferase. Modulation by initiation factor eIF4E. J Biol Chem 1991; 266: 16518-23.
57. Shantz LM, Viswanath R, Pegg AE. Role of the 5′-untranslated region of the mRNA in the synthesis of S-adenosylmethionine decarboxylase and its regulation by spermine. Biochem J 1994; 302: 765-72.
58. Marth JD, Overell RW, Meier KE et al. Translational activation of the lck proto-oncogene. Nature 1988; 332: 171-3.
59. Hoover DS, Wingett DG, Zhang J et al. Pim-1 protein expression is regulated by its 5′-untranslated region and translation initiation factor eIF4E. Cell Growth Diff 1997; 8: 1371-80.
60. Abid MR, Li Y, Anthony C et al. Translational regulation of ribonucleotide reductase by eukaryotic initiation factor 4E links protein synthesis to the control of DNA replication. J Biol Chem 1999; 274: 35991-8.
61. Bommer UA, Lazaris-Karatzas A, De Benedetti A et al. Translational regulation of the mammalian growth-related protein P23: Involvement of eIF-4E. Cell Mol Biol Res 1994; 40: 633-41.
62. Jiang Y, Muschel RJ. Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res 2002; 62: 1910-4.
63. Pardo OE, Arcaro A, Salerno G et al. Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: Correlation with resistance to etoposide-induced apoptosis. J Biol Chem 2002; 277: 12040-6.
64. Short JD, Pfarr CM. Translational regulation of the JunD messenger RNA. J Biol Chem 2002; 277: 32697-705.
65. Li Y, DeFatta R, Anthony C et al. A translationally regulated Tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene 2001; 20: 726-38.
66. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062-74.
67. Boylan JF, Jackson J, Steiner MR et al. Role of the Ha-ras (RasH) oncogene in mediating progression of the tumor cell phenotype. Anticancer Res 1990; 10: 717-24 (Review).
68. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 2000; 1470: M21-35.
69. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
70. Graff JR. Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Exp Opin Ther Targets 2002; 6: 103-13.
71. Huang S, Houghton PJ. Resistance to rapamycin: A novel anticancer drug. Cancer Metastasis Rev 2001: 20: 69-78.
72. Dilling MB, Germain GS, Dudkin L et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002; 277: 13907-17.
73. DeBenedetti A, Harris A. eIF4E expression in tumours. Int J Biochem Cell Biol 1999; 31: 59-72.
74. Kerekatte V, Smiley K, Hu B et al. The protooncogene/translation factor eIF-4E - a survey of its expression in breast carcinomas. Int J Cancer 1995; 65: 27-31.
75. Nathan CA, Carter P, Liu L et al. Elevated expression of eIF-4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 1997; 15: 1087-95.
76. Li BDL, Liu L, Dawson M et al. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 1997; 79: 2385-9.
77. Li BDL, McDonald J, Nassar R et al. Clinical outcome in stage 1 to 3 breast carcinomas and eIF4E overexpression. Ann Surg Soc 1998; 227: 756-62.
78. DeFatta RJ, Turbat-Herrera EA, Li BD et al. Elevated expression of eIF-4E in confined early breast cancer lesions: Possible role of hypoxia. Int J Cancer 1999; 80: 516-22.
79. Anthony B, Carter P, DeBenedetti A. Overexpression of the protooncogene/translation factor 4E in breast-carcinoma cell lines. Int J Cancer 1996; 65: 858-63.
80. Haydon MS, Googe JD, Sorrells DS et al. Progression of eIF4E gene amplification and overexpression in benign and malignant tumors of the head and neck. Cancer 2000; 88: 2803-10.
81. Nathan CA, Sanders K, Abreo FW et al. Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: Prognostic implications. Cancer Res, 2000; 60: 3599-604.
82. Nathan CA, Liu L, Li B et al. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene 1997; 15: 579-84.
83. Franklin S, Pho T, Abreo FW et al. Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers. Arch Otolaryngol Head Neck Surg 1999; 125: 177-82.
84. Sorrells DL Jr, Ghali GE, DeBenedetti A et al. Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers. J Oral Maxillofac Surg 1999; 57: 294-99.
85. Wang S, Rosenwald IB, Hutzler MJ et al. Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. Am J Pathol 1999; 155: 247-55.
86. Martin ME, Perez MI, Redondo C et al. 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol 2000; 32: 633-42.
87. Crew JP, Fuggle S, Bicknell R et al. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumor progression. Br J Cancer 2000; 82: 161-6.
88. Rosenwald IB, Chen JJ, Wang S et al. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999; 18: 2507-17.
89. Fowler CL, Zimmer CC, Zimmer SG. Spontaneous progression of a stage IV-S human neuroblastoma cell line involves the increased expression of the protooncogenes ras and eukaryotic initiation factor 4E. Pediatr Pathol Mol Med 2000; 19: 433-47.
90. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA cap. Nature 1990; 345: 544-7.
91. Lazaris-Karatzas A, Sonenberg N. The mRNA 5′ cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transforming of primary rodent fibroblasts. Mol Cell Biol 1992; 12: 1234-8.
92. Lazaris-Karatzas A, Smith MR, Frederickson RM et al. Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev 1992; 6: 1631-42.
93. Klein PS, Melton DA. Induction of mesoderm in Xenopus laevis embryos by translation initiation factor 4E. Science 1994; 265: 803-5.
94. Polunovsky VA, Gingras AC, Sonenberg N et al. Translational control of the antiapoptotic function of Ras. J Biol Chem 2000; 275: 24776-80.
95. Tan A, Bitterman P, Sonenberg N et al. Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. Oncogene 2000; 19: 1437-47.
96. Polunovsky VA, Rosenwald IB, Tan AT et al. Translational control of programmed cell death: Eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 1996; 16: 6573-81.
97. Herbert TP, Fahraeus R, Prescott A et al. Rapid induction of apoptosis mediated by peptides that bind initiation factor 4E. Curr Biol 2000; 10: 793-6.
98. Rinker-Schaeffer CW, Graff JR, DeBenedetti A et al. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int J Cancer 1993; 55: 841-7.
99. Graff JR, Boghaert ER, DeBenedetti A et al. Reduction of translation initiation factor 4E reduces tumor growth, invasion and metastasis of ras-transformed cloned rat embryo fibroblast. Int J Cancer 1995; 60: 255-63.
100. DeFatta RJ, Nathan CA, DeBenedetti A. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 2000; 110: 928-33.
101. Rousseau, D., Gingras A-C, Pause A et al. The eIF-4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 1996; 13: 2415-20.
102. Tamm I, Dorken B, Hartmann G. Antisense therapy in oncology: New hope for an old idea. Lancet 2001; 358: 489-97.
103. Holmlund JT, Monia BP, Kwoh TJ et al. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Curr Opin Mol Ther 1999; 1: 372-85.
104. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35.
105. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-9.
106. Podsypanina K, Lee RT, Politis C et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Ptenmice. Proc Natl Acad Sci USA 2001; 98: 10320-5.
107. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19: 6680-6.
108. DeFatta RJ, Li Y, De Benedetti A. Selective killing of cancer cells based on translational control of a suicide gene. Cancer Gene Ther 2002; 9: 573-8.
109. DeFatta RJ, Chervenak RP, De Benedetti A. A cancer gene therapy approach through translational control of a suicide gene. Cancer Gene Ther 2002; 9: 505-12.
110. Ramaswamy S, Ross KN, Lander ES and Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Gen 2003; 33: 49-54.